Table 6.

Mental Health Treatment of Patients With Schizophrenia During the 45 Days After Discontinuing FD, HD, or LAR

	FD Patients, % (N = 816)	HD Patients, % (N = 1301)	LAR Patients, % (N = 102)	Statistics			Group Differencesa
Medication				χ2	df	P
Any oral antipsychotic	77.4	78.9	75.5	1.1	2	.57
Oral antipsychotic medications
Fluphenazine	24.0	1.7	4.9	279.7	2	<.0001	FD > LAR > HD
Haloperidol	6.0	23.5	7.8	118.1	2	<.0001	HD > FD, LAR
Risperidone	20.1	21.6	43.4	28.4	2	<.0001	LAR>FD, HD
Olanzapine	30.0	30.0	23.5	1.9	2	.39
Quetiapine	21.4	19.1	13.7	4.2	2	.12
Ziprasidone	6.5	6.1	4.9	0.4	2	.80
Aripiprazole	2.0	3.1	5.9	6.0	2	.049	LAR > FD
Clozapine	7.8	7.6	5.9	0.5	2	.78
Other psychotropic medications
Antidepressant	38.2	33.9	39.2	4.7	2	.10	FD > HD
Anxiolytic/hypnotic	34.9	29.8	36.3	7.1	2	.03	FD > HD
Mood stabilizer	46.6	45.5	35.3	2.7	2	.26	FD, HD > LAR
Antipsychotic gap of >30 days among oral users	5.5	6.6	9.1	1.8	2	.41
Antipsychotic MPRb <0.80	35.9	38.7	48.0	6.2	2	.046	LAR > FD
Acute mental health care (%)
Emergency visit	8.1	6.2	6.9	2.9	2	.23
Hospital admission	0.6	0.6	0	0.6	2	.73

Note: Data from 2001 to 2004 Medi-Cal. FD denotes fluphenazine decanoate, HD denotes haloperidol decanoate, and LAR denotes long-acting risperidone.

^aGroup differences, P < .05.

^bMPR denotes medication possession ratio and is defined as the proportion of days of any antipsychotic medication treatment during the 45 days after depot injection treatment.